Neurofilament light chain in the assessment of patients with multiple sclerosis

Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis

(2018) Christian Barro et al.   BRAIN

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome

(2018) Clara Matute-Blanch et al.   BRAIN

Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis

(2018) Irene Håkansson et al.   Journal of Neuroinflammation

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis

(2018) Nelly Siller et al.   Multiple Sclerosis Journal

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis

(2018) Nelly Siller et al.   Multiple Sclerosis Journal

Brazilian Consensus for the Treatment of Multiple Sclerosis: Brazilian Academy of Neurology and Brazilian Committee on Treatment and Research in Multiple Sclerosis

(2018) Vanessa Daccach Marques et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Neurofilaments and 10-year follow-up in multiple sclerosis

(2018) Alok Bhan et al.   Multiple Sclerosis Journal

Vitamin D supplementation and neurofilament light chain in multiple sclerosis

(2018) Trygve Holmøy et al.   ACTA NEUROLOGICA SCANDINAVICA

Correlation of clinical findings and brain volume data in multiple sclerosis

(2017) Yara Dadalti Fragoso et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Fluid biomarker and electrophysiological outcome measures for progressive MS trials

(2017) Christian Barro et al.   Multiple Sclerosis Journal

Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis

(2017) Carla Tortorella et al.   Multiple Sclerosis Journal

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

(2017) Lenka Novakova et al.   NEUROLOGY

Fluid biomarker and electrophysiological outcome measures for progressive MS trials

(2017) Christian Barro et al.   Multiple Sclerosis Journal

Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis

(2017) Carla Tortorella et al.   Multiple Sclerosis Journal

Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis

(2016) J. Mellergård et al.   EUROPEAN JOURNAL OF NEUROLOGY

Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?

(2016) Sahil Gupta et al.   Expert Review of Neurotherapeutics

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis

(2016) Lenka Novakova et al.   JOURNAL OF NEUROCHEMISTRY

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

(2016) Lenka Novakova et al.   Multiple Sclerosis Journal

Neurofilament light chain level is a weak risk factor for the development of MS

(2016) Georgina Arrambide et al.   NEUROLOGY

Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?

(2016) Sahil Gupta et al.   Expert Review of Neurotherapeutics

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis

(2016) Lenka Novakova et al.   Multiple Sclerosis Journal

Overview of magnetic resonance imaging for management of relapsing−remitting multiple sclerosis in everyday practice

(2015) C. Oreja-Guevara   EUROPEAN JOURNAL OF NEUROLOGY

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

(2015) J. Kuhle et al.   NEUROLOGY

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

Is it time to target no evident disease activity (NEDA) in multiple sclerosis?

(2015) Gavin Giovannoni et al.   Multiple Sclerosis and Related Disorders

Assessing tissue damage in multiple sclerosis: a biomarker approach

(2014) J. Burman et al.   ACTA NEUROLOGICA SCANDINAVICA

Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis

(2013) Lenka Fialová et al.   JOURNAL OF NEUROIMMUNOLOGY

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

(2013) Markus Axelsson et al.   Multiple Sclerosis Journal

A comparative study of CSF neurofilament light and heavy chain protein in MS

(2013) Jens Kuhle et al.   Multiple Sclerosis Journal

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases

(2013) Johanna Gaiottino et al.   PLoS One

CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis

(2012) Jeppe Romme Christensen et al.   Multiple Sclerosis Journal

CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome

(2012) M Khalil et al.   Multiple Sclerosis Journal

Protein biomarkers for multiple sclerosis: semi-quantitative analysis of cerebrospinal fluid candidate protein biomarkers in different forms of multiple sclerosis

(2012) Timucin Avsar et al.   Multiple Sclerosis Journal

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

(2010) Martin Gunnarsson et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the ‘Spinal Tap’

(2010) Gavin Giovannoni   Multiple Sclerosis Journal